This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Semaglutide, the popular drug sold by Novo Nordisk as ...
Several common drugs will be cheaper next year under Medicare, from weight-loss drug Ozempic to breast-cancer medication ...
FILE PHOTO: The Pfizer logo is seen at their world headquarters in Manhattan, New York, U.S. (Reuters) - Pfizer Inc said on Friday its cancer drug Ibrance did not meet the main goal in a late-stage ...
Savings will help people struggling with high drug prices and improve access to life-saving medications for Medicare Part D ...
The breast cancer medication Ibrance has been the shooting star in Pfizer’s universe, and it’s expected to burn brightly enough to raise the entire company’s fortunes. That’s despite Ibrance’s ...
Matthew Herper covers medical innovation — both its promise and its perils. Pfizer said Thursday its drug Ibrance showed efficacy in a group of breast cancer patients who do not currently have access ...
Econostrum on MSN
Medicare price revolution: Which drugs will cost you less next year?
For many, these price reductions may represent a critical step in improving access to essential medications, especially as ...
Those were the findings of the phase 3 PALOMA-3 trial, presented May 30 during the 2015 annual meeting of the American Society of Clinical Oncology (ASCO), a gathering of nearly 30,000 oncology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback